Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02753777 · ClinicalTrials.gov registry record
Autoimmune Blistering Diseases Study
A clinical trial of Pemphigus Vulgaris and Bullous Pemphigoid, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- 150
- Enrollment target
- 3
- Study locations
NCT02753777: Recruiting study of Pemphigus Vulgaris and Bullous Pemphigoid, sponsored by University of Pennsylvania.
NCT02753777 is a study of Pemphigus Vulgaris and Bullous Pemphigoid that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 150 participants. The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02753777, a study of Pemphigus Vulgaris and Bullous Pemphigoid, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 3
- Study locations
Study Summary
Pemphigus and bullous pemphigoid (BP) are severe autoimmune blistering diseases (AIBD) that pose a critical need for new therapeutic approaches. Clinical trials in pemphigus and BP will require the availability of validated disease severity measures that can be used to define primary outcomes.
Conditions Studied
Interventions
- OTHER Questionnaires
Study Locations (3)
Pennsylvania
- Hospital of the University of Pennsylvania, Department of Dermatology - Philadelphia
- Hospital of the University of Pennsylvania - Philadelphia
- University of Pennsylvania, Department of Dermatology - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2016-04 |
| Est. Completion | 2030-01-02 |
What NCT02753777 shows while recruiting
NCT02753777 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap.
The record links to 3 conditions, with Pemphigus Vulgaris appearing as the primary indexed condition, and to 1 intervention - of which Questionnaires is the first listed.
NCT02753777 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02753777 about?
NCT02753777 is a clinical study titled "Autoimmune Blistering Diseases Study". Pemphigus and bullous pemphigoid (BP) are severe autoimmune blistering diseases (AIBD) that pose a critical need for new therapeutic approaches. Clinical trials in pemphigus and BP will require the availability of validated disease severity measures that can be used to define primary outcomes.
What is the current status of trial NCT02753777?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2016-04. Estimated completion is 2030-01-02.
What conditions does trial NCT02753777 study?
This clinical trial studies the following conditions: Pemphigus Vulgaris, Bullous Pemphigoid, Pemphigus Foliaceus.
What interventions are being tested in trial NCT02753777?
The interventions under investigation include: Questionnaires (OTHER).
Who is sponsoring clinical trial NCT02753777?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02753777 being conducted?
This trial has 3 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pemphigus Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
RECRUITING · Phase 1
-
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia